OMEICOS Therapeutics

Executive Summary

OMEICOS Therapeutics is a private German biopharmaceutical company focused on developing small-molecule therapies for cardiovascular diseases. Its lead candidate, OMT-28, is a novel modulator targeting inflammation and fibrosis pathways implicated in atrial fibrillation (AF). In a recent double-blind, placebo-controlled Phase 2 trial, OMT-28 demonstrated an excellent safety and tolerability profile, consistent with Phase 1 results. The trial enrolled patients with AF, and while full efficacy data have not yet been disclosed, the safety profile supports further development. Founded in 2010 and based in Berlin, OMEICOS is advancing OMT-28 toward Phase 3, positioning it as a potential first-in-class treatment for AF, a condition affecting millions worldwide with high unmet need. The company’s near-term value inflection hinges on the release of Phase 2 efficacy results, which could validate OMT-28’s mechanism and de-risk the program. Positive data would enable discussions with regulatory authorities and potential partners, while negative outcomes would likely stall development. OMEICOS operates in a competitive landscape but benefits from a differentiated approach targeting underlying disease drivers rather than just symptoms. The company’s private status means funding and partnership news are key catalysts. With a disciplined development strategy and a promising safety profile, OMEICOS represents a speculative but potentially high-impact opportunity in cardiovascular therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Efficacy Results for OMT-28 in Atrial Fibrillation70% success
• Q2 2027Regulatory Guidance Meeting (FDA/EMA) for Phase 3 Program60% success
• 2027Strategic Partnership or Licensing Deal for OMT-2840% success